Aardvark Therapeutics, Inc. 8K

Aardvark Therapeutics reported Q1 2026 results, disclosing voluntary pauses of its ARD-101 and ARD-201 clinical programs due to reversible cardiac findings in a safety study, while maintaining sufficient cash runway into mid-2027 and working with the FDA to determine next steps.

On May 7, 2026, Aardvark Therapeutics, Inc. reported its unaudited financial results for the quarter ended March 31, 2026, and disclosed that it has voluntarily paused enrollment and dosing in its Phase 3 HERO and open-label extension trials of ARD-101 for Prader-Willi Syndrome, as well as its ARD-201 obesity program, following unexpected but reversible cardiac observations in a separate healthy volunteer safety study. The company is conducting a comprehensive data review in collaboration with the FDA and expects to provide additional guidance on the future of both ARD-101 and ARD-201 in the second quarter of 2026. Aardvark ended the quarter with $91.2 million in cash, cash equivalents and short-term investments, which it believes will fund operations into mid-2027, and reported a first-quarter 2026 net loss of $21.6 million driven by increased R&D and G&A expenses associated primarily with ARD-101 development and public company costs. The company also highlighted the publication of Phase 2 and related preclinical ARD-101 data in the journal Molecular Metabolism, supporting the mechanism of action in hunger and hyperphagia and reinforcing the strategic importance of the paused programs.

Filing Facts

CIK

1774857

Ticker

-

Form

8K

Source Type

sec

Accession

0001193125-26-210664

Alert Tier

7